NAPOLI 1: A Randomized, Open Label Phase 3 Study of MM-398, with or without 5-Fluorouracil and Leucovorin, versus 5-Fluorouracil and Leucovorin, in Patients with Metastatic Pancreatic Cancer Who have Failed Prior Gemcitabine-based Therapy

Trial Profile

NAPOLI 1: A Randomized, Open Label Phase 3 Study of MM-398, with or without 5-Fluorouracil and Leucovorin, versus 5-Fluorouracil and Leucovorin, in Patients with Metastatic Pancreatic Cancer Who have Failed Prior Gemcitabine-based Therapy

Completed
Phase of Trial: Phase III

Latest Information Update: 20 Jun 2018

At a glance

  • Drugs Irinotecan (Primary) ; Fluorouracil; Folinic acid
  • Indications Adenocarcinoma; Pancreatic cancer
  • Focus Registrational; Therapeutic Use
  • Acronyms NAPOLI-1
  • Sponsors Merrimack Pharmaceuticals
  • Most Recent Events

    • 20 Jun 2018 According to a Shire media release, results from the trial presented at the 20thESMO World Congress on Gastrointestinal Cancer 2018 (ESMO-GI)
    • 05 Jun 2018 Results of post- hoc analysis developing a nomogram to predict OS for nal-IRI+5-FU/LV in the post-gemcitabine setting presented at the 54th Annual Meeting of the American Society of Clinical Oncology
    • 20 Jan 2018 Results of post-hoc subgroup analysis assessing weight-related parameter presented at the 2018 Gastrointestinal Cancers Symposium
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top